Trending...
- City Council invites community engagement: Volunteer for Colorado Springs Boards, Commissions, and Committees
- Colorado Springs: Summer Sunrise Openings on Pikes Peak – America's Mountain
- Colorado Springs: Phil Long Dealerships donates $10,000 to City's Keep It Clean COS initiative
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
BEAVERTON, Ore. - ColoradoDesk -- Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities. Equipped with multiple state of the art, environmentally controlled production, quality and research laboratories, high throughput production equipment, and expanded warehouse capacity, the facility is also designed to accommodate the "new normal" of business in a pandemic challenged environment. The new facility will have a much needed immediate impact on production capacity of Sedia's products, now being used in partnership with the U.S. Centers for Disease Control and Prevention (CDC, www.cdc.gov), PEPFAR (President's Emergency Plan for AIDS Relief, www.pepfar.gov), and other NGOs and stakeholders working with Sedia.
More on Colorado Desk
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Colorado Desk
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
More on Colorado Desk
- FloWater Gets Naked: New Campaign Strips Down the Dirty Truth About What's in Your Water
- New for Sonbuoy Electronics Improved Performance, smaller size, lower cost and weight
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Colorado Desk
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- OtterBox Unveils Summer's Must-Have Threads with New Cactus Leather Embroidery Cases
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Bed Bugs Exterminator at Your Service!
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
Filed Under: Health
0 Comments
Latest on Colorado Desk
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Injured at Work? Local Workers' Comp Attorneys in Grand Junction Offer Free Consultations
- What Makes Apple Grove Dental a Trusted Name for Dental Implants in Colorado Springs
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Colorado: Governor Polis Verbally Declares Disaster Declaration For Wildfires in Montrose, Delta and Mesa County
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Chaddrick Thomas Launches Two Inspiring New Podcasts:
- Dr. Gregory A. Thomas Launches Bold New Podcast, Real Talk with Dr. Gregory A. Thomas
- Colorado Springs celebrates one year of Pikes Peak Rising, a community-powered movement for mental health
- Colorado Springs: Ramona Avenue at South Nevada Avenue to close on Monday
- Colorado Springs: Northbound Tejon Street to reopen on block downtown
- City of Colorado Springs, El Paso County invite public to open houses for Housing Needs Assessment
- Colorado Springs: Did you know? — Evergreen Cemetery's Roses
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market